S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33

Turning Point Therapeutics (TPTX) Stock Forecast, Price & News

+0.79 (+2.48%)
(As of 05/26/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
476,607 shs
Average Volume
592,255 shs
Market Capitalization
$1.62 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Turning Point Therapeutics logo

About Turning Point Therapeutics

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.


Expert Ratings for Turning Point
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$30.83 million
Book Value
$17.95 per share


Net Income
$-236.55 million
Pretax Margin




Free Float
Market Cap
$1.62 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.92 out of 5 stars

Medical Sector

673rd out of 1,424 stocks

Pharmaceutical Preparations Industry

318th out of 681 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

Is Turning Point Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics
or view top-rated stocks.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Turning Point Therapeutics

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.51) by $0.01. The business earned $0.40 million during the quarter. The firm's quarterly revenue was down 98.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.73) earnings per share.
View Turning Point Therapeutics' earnings history

What price target have analysts set for TPTX?

10 brokers have issued twelve-month price targets for Turning Point Therapeutics' stock. Their forecasts range from $45.00 to $161.00. On average, they anticipate Turning Point Therapeutics' share price to reach $92.25 in the next year. This suggests a possible upside of 183.0% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Turning Point Therapeutics' key executives?
Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis M.D., Pres, CEO & Director (Age 50, Pay $1.13M)
  • Ms. Annette C. North Esq., LLB, Exec. Officer (Age 56, Pay $641.8k) (LinkedIn Profile)
  • Mr. Andrew John Partridge, Exec. VP & Chief Commercial Officer (Age 53, Pay $979.04k) (LinkedIn Profile)
  • Mr. Paolo Tombesi, Exec. VP & CFO (Age 58)
  • Mr. Ed Gemo, Sr. VP & Chief Information Officer
  • Dr. Adam D. Levy M.B.A., Ph.D., Sr. VP of Investor Relations & Corp. Communications
  • Mr. Raymond J. Furey J.D., Sr. VP & Chief Compliance Officer (Age 54)
  • Mr. Brian Sun J.D., M.S., Sr. VP & Gen. Counsel
  • Ms. Heather Adams, VP of HR
  • Dr. Jeffrey P. Whitten, Sr. VP of Pre-Clinical Devel.
What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.12%), Vanguard Group Inc. (7.88%), BlackRock Inc. (7.43%), State Street Corp (6.28%), Federated Hermes Inc. (4.18%) and Goldman Sachs Group Inc. (1.70%). Company insiders that own Turning Point Therapeutics stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Siegfried Reich and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics

Which institutional investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Frontier Capital Management Co. LLC, BlackRock Inc., Citigroup Inc., Candriam Luxembourg S.C.A., International Biotechnology Trust PLC, Allianz Asset Management GmbH, and UBS Group AG. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Andrew John Partridge, Annette North, Athena Countouriotis, and Siegfried Reich.
View insider buying and selling activity for Turning Point Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Turning Point Therapeutics stock?

TPTX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., JPMorgan Chase & Co., Sectoral Asset Management Inc., Dimensional Fund Advisors LP, Goldman Sachs Group Inc., PDT Partners LLC, and Vanguard Group Inc..
View insider buying and selling activity for Turning Point Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $32.60.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics has a market capitalization of $1.62 billion and generates $30.83 million in revenue each year. The company earns $-236.55 million in net income (profit) each year or ($5.56) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

Turning Point Therapeutics employs 250 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 926-5251 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.